etidronate has been researched along with Hypercalcemia in 81 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Hypercalcemia: Abnormally high level of calcium in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days." | 9.07 | Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. ( Lad, TE; Recker, RR; Ringenberg, QS; Ritch, PS; Ryzen, E; Schiller, JH; Singer, FR, 1991) |
| "Etidronate, when administered intravenously at 30 mg/kg during a period of 24 hours, apparently was safe and effective in this study for treatment of hypercalcemia in patients with a wide variety of tumor types." | 9.07 | Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. ( Belani, CP; Chang, AY; Chapman, RA; Flores, JF; Hoff, JV; Pritchard, JD; Rude, RK, 1994) |
| "A dose-ranging, baseline-controlled study was undertaken to assess the safety and effectiveness of a 24-hour infusion of etidronate disodium in treating patients with hypercalcemia of malignant disease." | 9.07 | Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study. ( Flores, JF; Rude, RK; Singer, FR, 1991) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 9.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11." | 9.06 | Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. ( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987) |
| "To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate, 7." | 9.06 | Etidronate disodium in the management of malignancy-related hypercalcemia. ( Charles, P; Hasling, C; Mosekilde, L, 1987) |
| " While the exact mechanism of action remains poorly understood, etidronate, the only bisphosphonate currently available in the United States for the treatment of hypercalcemia, decreases the elevated serum calcium levels and alleviates the symptoms associated with hypercalcemia of malignancy." | 8.78 | Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. ( Singer, FR, 1990) |
| "Nineteen patients with Paget's disease and four patients with hypercalcemia of malignancy underwent hypocalcemic therapy with etidronate disodium (etidronate) administered intravenously." | 7.67 | Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. ( Arlot, M; Chapuy, MC; Charhon, S; Delmas, P; Edouard, C; Meunier, PJ, 1987) |
| "Following a four-day control period during which an elevated serum calcium level either stabilized or continued to rise despite maximally tolerated saline diuresis, 12 patients with neoplastic hypercalcemia were treated with intravenous etidronate disodium (etidronate) 7." | 7.67 | Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. ( Clemens, TL; Gordon, AC; Gundberg, CM; Jacobs, TP; Reich, L; Shane, E; Silverberg, SJ, 1987) |
| "Etidronate was administered as a 4-hour IV infusion at a dose of 7." | 6.67 | A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. ( Heller, G; Murphy, WK; O'Dwyer, PJ; Schulman, P; Warrell, RP, 1991) |
| "Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia." | 6.40 | Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. ( Rice, AM; Rivkees, SA, 1999) |
| "Subcutaneus fat necrosis is an uncommon disease which may be complicated with potentially fatal hypercalcemia." | 5.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "It is attributed to an increase in bone resorption and diminished bone formation characterized clinically by elevated serum calcium levels, hypercalciuria, increased risk of urinary lithiasis, and renal failure." | 5.29 | Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. ( Cross, LL; Meythaler, JM; Tuel, SM, 1993) |
| "Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy." | 5.28 | Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. ( Fatemi, S; Rude, RK; Singer, FR, 1992) |
| " Treatments were as follows: idiopathic osteoporosis: calcium and vitamin D supplements (N = 10) or cyclical etidronate for 2 weeks followed by calcium and vitamin D supplements for 76 days (N = 29); moderate idiopathic phosphate diabetes: calcitriol and phosphate (N = 15); idiopathic hypercalciuria: hydrochlorothiazide (N = 6); and hypogonadism: testosterone (N = 3)." | 5.09 | Management of male osteoporosis. ( Catanzariti, L; Cortet, B; Delcambre, B; Grardel, B; Marchandise, X; Vasseur, J, 2001) |
| "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days." | 5.07 | Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. ( Lad, TE; Recker, RR; Ringenberg, QS; Ritch, PS; Ryzen, E; Schiller, JH; Singer, FR, 1991) |
| "Etidronate, when administered intravenously at 30 mg/kg during a period of 24 hours, apparently was safe and effective in this study for treatment of hypercalcemia in patients with a wide variety of tumor types." | 5.07 | Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. ( Belani, CP; Chang, AY; Chapman, RA; Flores, JF; Hoff, JV; Pritchard, JD; Rude, RK, 1994) |
| "A dose-ranging, baseline-controlled study was undertaken to assess the safety and effectiveness of a 24-hour infusion of etidronate disodium in treating patients with hypercalcemia of malignant disease." | 5.07 | Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study. ( Flores, JF; Rude, RK; Singer, FR, 1991) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 5.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11." | 5.06 | Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. ( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987) |
| "As part of a multicenter trial of etidronate disodium for control of hypercalcemia in patients with malignancies, patients achieving normocalcemia within seven days after starting intravenous therapy with etidronate disodium plus saline were enrolled into a double-blind, placebo-controlled trial of oral etidronate disodium to maintain normocalcemia." | 5.06 | Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. ( Ringenberg, QS; Ritch, PS, 1987) |
| "To evaluate the efficacy of intravenous etidronate disodium (etidronate) in controlling hypercalcemia of malignancy, 20 patients with known malignant disease and hypercalcemia were randomly assigned on a two-to-one basis to receive etidronate, 7." | 5.06 | Etidronate disodium in the management of malignancy-related hypercalcemia. ( Charles, P; Hasling, C; Mosekilde, L, 1987) |
| " While the exact mechanism of action remains poorly understood, etidronate, the only bisphosphonate currently available in the United States for the treatment of hypercalcemia, decreases the elevated serum calcium levels and alleviates the symptoms associated with hypercalcemia of malignancy." | 4.78 | Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. ( Singer, FR, 1990) |
| "Recent information on the pathophysiology and treatment of hypercalcemia of malignancy is reviewed, and the roles of two new agents, gallium nitrate and pamidronate, are discussed." | 4.78 | Update on the medical treatment of hypercalcemia of malignancy. ( Hall, TG; Schaiff, RA, 1993) |
| " A 28-day-old neonate, presenting with SCFN, hypercalcemia and nephrocalcinosis was managed with intravenous saline followed by furosemide, oral prednisolone, potassium citrate and etidronate." | 3.73 | Subcutaneous fat necrosis with hypercalcemia. ( Nammalwar, BR; Prahlad, N; Shanmughasundharam, R; Vijayakumar, M, 2006) |
| "Clodronate, etidronate and pamidronate are bisphosphonates introduced in the treatment of hypercalcaemia and osteoporosis." | 3.70 | Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. ( Kalliovalkama, J; Kankaanranta, H; Lähteenmäki, T; Pörsti, I; Salenius, JP; Sisto, T; Wu, X; Ylitalo, P; Ylitalo, R, 1998) |
| "To define the nature, incidence and consequence of a possible interaction between etidronate (for the treatment of hypercalcemia) and methylene diphosphonate labelled with technetium-99m (99mTc-MDP) (for bone scanning)." | 3.69 | Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. ( Line, BR; Malfetano, J; Murphy, KJ, 1997) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "Etidronate disodium (EHDP) therapy is often instituted emergently for treatment of hypercalcemia associated with malignancy, and a staging bone scan is part of the evaluation of the patient with extensive metastatic disease." | 3.68 | Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. ( Eary, JF; Hommeyer, SH; Varney, DM, 1992) |
| "Following a four-day control period during which an elevated serum calcium level either stabilized or continued to rise despite maximally tolerated saline diuresis, 12 patients with neoplastic hypercalcemia were treated with intravenous etidronate disodium (etidronate) 7." | 3.67 | Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. ( Clemens, TL; Gordon, AC; Gundberg, CM; Jacobs, TP; Reich, L; Shane, E; Silverberg, SJ, 1987) |
| "Nineteen patients with Paget's disease and four patients with hypercalcemia of malignancy underwent hypocalcemic therapy with etidronate disodium (etidronate) administered intravenously." | 3.67 | Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. ( Arlot, M; Chapuy, MC; Charhon, S; Delmas, P; Edouard, C; Meunier, PJ, 1987) |
| "Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia." | 3.66 | [Treatment of hypercalcemia of tumoral origin with two diphosphonates]. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1980) |
| "Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia." | 3.66 | Parenteral diphosphonates for treating malignant hypercalcemia. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1981) |
| "Etidronate was administered as a 4-hour IV infusion at a dose of 7." | 2.67 | A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. ( Heller, G; Murphy, WK; O'Dwyer, PJ; Schulman, P; Warrell, RP, 1991) |
| "Indomethacin was effective in only one of five patients to whom it was given, and EHDP was effective also in only one of five patients." | 2.65 | Comparative study of available medical therapy for hypercalcemia of malignancy. ( Heath, DA; Mundy, GR; Wilkinson, R, 1983) |
| "Hypercalcemia was confirmed by laboratory examination." | 2.53 | Systemic lupus erythematosus-related hypercalcemia with ectopic calcinosis. ( Huang, L; Zhang, X; Zhao, L, 2016) |
| "Specific treatment of cancer remains essential to prevent TIH relapse." | 2.41 | [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001) |
| "Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures." | 2.41 | Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000) |
| "Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts." | 2.41 | Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002) |
| "Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia." | 2.40 | Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. ( Rice, AM; Rivkees, SA, 1999) |
| "This is particularly true in multiple myeloma (MM), where bone involvement markedly influences the quality of life of patients." | 2.40 | The role of bisphosphonates for the treatment of bone disease in multiple myeloma. ( Musto, P, 1998) |
| " These findings, coupled with the knowledge that suppression of bone resorption persists for the duration of treatment, has led to the long term use of oral doses of clodronate to decrease the incidence of complications of osteolytic bone disease." | 2.40 | Clodronate. ( Kanis, JA; McCloskey, EV, 1997) |
| "Treatment of cancer associated hypercalcaemia is based on an initial phase of volume repletion with isotonic saline, followed by drug treatment to inhibit bone resorption." | 2.39 | Pathogenesis and management of cancer associated hypercalcaemia. ( Ralston, SH, 1994) |
| " Mineralisation defects in forming bone may be avoided by the use of an initial dosage of 5 mg/kg/day for up to 6 months; dosages above 10 mg/kg/day should be limited to 3 months' duration, and dosages greater than 20 mg/kg/day should be avoided." | 2.39 | Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. ( Dunn, CJ; Fitton, A; Sorkin, EM, 1994) |
| "Many agents are available for the treatment of hypercalcemia." | 2.38 | Medical treatment of hypercalcemia. ( Bar, RS; Hall, TG; Schaiff, RA, 1989) |
| "Subcutaneous fat necrosis (SCFN) is a rare entity that occurs generally in term or post-term newborns exposed to perinatal stressing factors." | 1.40 | Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy. ( Antón López, J; Apodaca Saracho, A; Camprubí Camprubí, M; García-Alix, A; Lopez Ramos, MG; Pérez Martínez, E; Ramos Cebrián, M, 2014) |
| "Subcutaneus fat necrosis is an uncommon disease which may be complicated with potentially fatal hypercalcemia." | 1.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| "It is attributed to an increase in bone resorption and diminished bone formation characterized clinically by elevated serum calcium levels, hypercalciuria, increased risk of urinary lithiasis, and renal failure." | 1.29 | Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. ( Cross, LL; Meythaler, JM; Tuel, SM, 1993) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "The bone marrow revealed acute myeloblastic leukemia." | 1.29 | Case report: hypercalcemia in acute myeloblastic leukemia is caused by osteoclast activation. ( Kent, AB; Weinstein, RS, 1993) |
| "Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy." | 1.28 | Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. ( Fatemi, S; Rude, RK; Singer, FR, 1992) |
| " The author discusses the administration, dosage and side effects, and results of current studies." | 1.28 | Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991) |
| "sarcoma 180 was in fact related to alterations of osseous tissues by EHDP." | 1.27 | Effects of disodium etidronate in murine tumor models. ( Coccioli, G; Corti, F; Donelli, MG; Filippeschi, S; Garattini, S; Guaitani, A; Italia, C; Mantovani, A; Marmonti, L; Polentarutti, N, 1984) |
| "Etidronate was also found to prevent bone metastasis in syngeneic rat mammary carcinoma." | 1.27 | Effect of etidronate disodium on the interactions between malignancy and bone. ( Garattini, S; Guaitani, A; Mantovani, A, 1987) |
| "Transient hypercalcemia was attributed to immobilization." | 1.26 | Tumoral calcinosis. Observations during six years. ( Haas, HG; Lauffenburger, T; Leicht, E; Seeliger, H; Tkocz, HJ, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (40.74) | 18.7374 |
| 1990's | 37 (45.68) | 18.2507 |
| 2000's | 9 (11.11) | 29.6817 |
| 2010's | 2 (2.47) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pérez Martínez, E | 1 |
| Camprubí Camprubí, M | 1 |
| Ramos Cebrián, M | 1 |
| Antón López, J | 1 |
| Apodaca Saracho, A | 1 |
| Lopez Ramos, MG | 1 |
| García-Alix, A | 1 |
| Zhao, L | 1 |
| Huang, L | 1 |
| Zhang, X | 1 |
| Berenson, JR | 1 |
| Caldwell, JW | 1 |
| Arsura, EL | 1 |
| Kilgore, WB | 1 |
| Reddy, CM | 1 |
| Johnson, RH | 1 |
| Neau-Cransac, M | 1 |
| Lepreux, S | 1 |
| Labreze, C | 1 |
| Quinart, A | 1 |
| Revel, P | 1 |
| Saric, J | 1 |
| Bioulac-Sage, P | 1 |
| Vijayakumar, M | 1 |
| Prahlad, N | 1 |
| Nammalwar, BR | 1 |
| Shanmughasundharam, R | 1 |
| Trullemans, B | 1 |
| Bottu, J | 1 |
| Van Nieuwenhuyse, JP | 1 |
| Mundy, GR | 1 |
| Wilkinson, R | 1 |
| Heath, DA | 1 |
| Kanis, JA | 5 |
| Paterson, AD | 1 |
| Russell, RG | 1 |
| Delmas, PD | 1 |
| Meunier, PJ | 2 |
| Hägg, E | 1 |
| Eklund, M | 1 |
| Tørring, O | 1 |
| Merli, GJ | 1 |
| McElwain, GE | 1 |
| Adler, AG | 1 |
| Martin, JH | 1 |
| Roberts, JD | 1 |
| Schnall, B | 1 |
| Ditunno, JF | 1 |
| Guaitani, A | 2 |
| Polentarutti, N | 1 |
| Filippeschi, S | 1 |
| Marmonti, L | 1 |
| Corti, F | 1 |
| Italia, C | 1 |
| Coccioli, G | 1 |
| Donelli, MG | 1 |
| Mantovani, A | 2 |
| Garattini, S | 2 |
| Amoroso, A | 1 |
| Petroni, S | 1 |
| Cavina, G | 1 |
| Caccavo, D | 1 |
| Raisz, LG | 1 |
| Jung, A | 2 |
| van Ouwenaller, C | 2 |
| Chantraine, A | 2 |
| Courvoisier, B | 2 |
| Zweig, JI | 1 |
| Shafer, N | 1 |
| Leicht, E | 1 |
| Tkocz, HJ | 1 |
| Seeliger, H | 1 |
| Lauffenburger, T | 1 |
| Haas, HG | 1 |
| Chabrier, G | 1 |
| Simon, C | 1 |
| Schlienger, JL | 1 |
| Imler, M | 1 |
| Azuma, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Dunn, CJ | 1 |
| Fitton, A | 1 |
| Sorkin, EM | 1 |
| Kent, AB | 1 |
| Weinstein, RS | 1 |
| Flores, JF | 2 |
| Rude, RK | 3 |
| Chapman, RA | 1 |
| Belani, CP | 1 |
| Chang, AY | 1 |
| Pritchard, JD | 1 |
| Hoff, JV | 1 |
| Meythaler, JM | 2 |
| Tuel, SM | 1 |
| Cross, LL | 1 |
| Hall, TG | 2 |
| Schaiff, RA | 2 |
| Kinirons, MT | 1 |
| Ralston, SH | 2 |
| Paterson, AH | 1 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Body, JJ | 2 |
| Coleman, RE | 2 |
| Piccart, M | 1 |
| Murphy, KJ | 1 |
| Line, BR | 1 |
| Malfetano, J | 1 |
| McCloskey, EV | 3 |
| Ylitalo, R | 1 |
| Kalliovalkama, J | 1 |
| Wu, X | 1 |
| Kankaanranta, H | 1 |
| Salenius, JP | 1 |
| Sisto, T | 1 |
| Lähteenmäki, T | 1 |
| Ylitalo, P | 1 |
| Pörsti, I | 1 |
| Musto, P | 1 |
| Rice, AM | 1 |
| Rivkees, SA | 1 |
| Oğuz, A | 1 |
| Karadeniz, C | 1 |
| Cağlar, E | 1 |
| Cağlar Citak, E | 1 |
| Ataoğlu, O | 1 |
| Bachrach, LK | 1 |
| Lum, CK | 1 |
| Cortet, B | 1 |
| Vasseur, J | 1 |
| Grardel, B | 1 |
| Catanzariti, L | 1 |
| Marchandise, X | 1 |
| Delcambre, B | 1 |
| Lortholary, A | 1 |
| Go, T | 1 |
| Goulding, A | 1 |
| Broom, MF | 1 |
| Schäfer, HJ | 1 |
| Riesner, K | 1 |
| Schlangen, JT | 1 |
| Pauwels, EK | 1 |
| Rosen, C | 1 |
| Segal, H | 1 |
| Hartz, CE | 1 |
| Mroz, F | 1 |
| Carlton, E | 1 |
| Warneke, G | 1 |
| Henning, HV | 1 |
| Warrell, RP | 4 |
| Hommeyer, SH | 1 |
| Varney, DM | 1 |
| Eary, JF | 1 |
| Fatemi, S | 1 |
| Singer, FR | 4 |
| Gucalp, R | 1 |
| Ritch, P | 1 |
| Wiernik, PH | 1 |
| Sarma, PR | 1 |
| Keller, A | 1 |
| Richman, SP | 1 |
| Tauer, K | 1 |
| Neidhart, J | 1 |
| Mallette, LE | 1 |
| Siegel, R | 1 |
| DeMeo, JH | 1 |
| Balseiro, J | 1 |
| Cole, TJ | 1 |
| List, A | 1 |
| Ritch, PS | 2 |
| Lad, TE | 1 |
| Ringenberg, QS | 2 |
| Schiller, JH | 2 |
| Recker, RR | 1 |
| Ryzen, E | 2 |
| Horowitz, E | 1 |
| Miller, JL | 1 |
| Rose, LI | 1 |
| Murphy, WK | 1 |
| Schulman, P | 1 |
| O'Dwyer, PJ | 1 |
| Heller, G | 1 |
| Sandler, ED | 1 |
| Parisi, MT | 1 |
| Hattner, RS | 1 |
| Gallacher, SJ | 1 |
| Parel, U | 1 |
| Boyle, IT | 1 |
| Bar, RS | 1 |
| Jacobs, TP | 1 |
| Gordon, AC | 1 |
| Silverberg, SJ | 1 |
| Shane, E | 1 |
| Reich, L | 1 |
| Clemens, TL | 1 |
| Gundberg, CM | 1 |
| Korkor, AB | 1 |
| Nanda, T | 1 |
| Kumar, NA | 1 |
| Fallon, M | 1 |
| Hasling, C | 2 |
| Charles, P | 2 |
| Mosekilde, L | 2 |
| Canfield, RE | 1 |
| Urwin, GH | 1 |
| Gray, RE | 1 |
| Beneton, MN | 1 |
| Hamdy, NA | 1 |
| Murray, SA | 1 |
| Chapuy, MC | 1 |
| Delmas, P | 1 |
| Charhon, S | 1 |
| Edouard, C | 1 |
| Arlot, M | 1 |
| Rasmussen, P | 1 |
| Benson, AB | 1 |
| Witte, RS | 1 |
| Bockman, RS | 1 |
| Harvey, HA | 1 |
| Siris, ES | 1 |
| Citrin, DL | 1 |
| Greco, FA | 1 |
| Stock, JL | 1 |
| Sasaki, H | 1 |
| Miyake, K | 1 |
| Okumura, M | 1 |
| Eimoto, T | 1 |
| Fleisch, H | 1 |
| Martodam, RR | 1 |
| Troxell, M | 1 |
| Benson, A | 1 |
| Paterson, A | 1 |
| Shepard, K | 1 |
| Hicks, R | 1 |
| Desablens, B | 1 |
| Sebert, JL | 1 |
| Claisse, JF | 1 |
| Pruna, A | 1 |
| Marié, A | 1 |
| Delobel, J | 1 |
| Messerschmitt, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 reviews available for etidronate and Hypercalcemia
| Article | Year |
|---|---|
Systemic lupus erythematosus-related hypercalcemia with ectopic calcinosis.
Topics: Adult; Biomarkers; Bone Density Conservation Agents; Calcinosis; Calcitonin; Cyclophosphamide; Drug | 2016 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H | 2002 |
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Bone Diseases; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Drug Administration Sched | 1994 |
Update on the medical treatment of hypercalcemia of malignancy.
Topics: Animals; Antineoplastic Agents; Calcitonin; Diphosphonates; Etidronic Acid; Gallium; Humans; Hyperca | 1993 |
Newer agents for the treatment of malignant hypercalcemia.
Topics: Diphosphonates; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1993 |
Pathogenesis and management of cancer associated hypercalcaemia.
Topics: Antineoplastic Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Diuretics; Etidronic Aci | 1994 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Clodronate.
Topics: Bone Diseases; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Etidronic Acid; Female; Hum | 1997 |
The role of bisphosphonates for the treatment of bone disease in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Remodeling; Clinical Trials as Topic; Clodronic Acid; Diphospho | 1998 |
Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn.
Topics: Etidronic Acid; Fat Necrosis; Humans; Hypercalcemia; Infant; Male; Remission Induction | 1999 |
Bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid | 2000 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog | 2001 |
[Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
Topics: Bone Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Oste | 1992 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
Etidronate for hypercalcemia of malignancy and osteoporosis.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Ossification, Heterotopic; Osteitis Deformans; Ost | 1991 |
Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
Topics: Animals; Etidronic Acid; Humans; Hypercalcemia; Molecular Structure; Neoplasms | 1990 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Medical treatment of hypercalcemia.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Calcitonin; Etidronic Acid; Homeos | 1989 |
[Biphosphonate as a therapeutic drug--experimental studies and clinical application].
Topics: Animals; Calcinosis; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperpar | 1985 |
14 trials available for etidronate and Hypercalcemia
| Article | Year |
|---|---|
Comparative study of available medical therapy for hypercalcemia of malignancy.
Topics: Administration, Oral; Adult; Aged; Calcium; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 1983 |
Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Topics: Adult; Aged; Calcium; Etidronic Acid; Female; Humans; Hypercalcemia; Infusions, Parenteral; Male; Mi | 1994 |
Management of male osteoporosis.
Topics: Absorptiometry, Photon; Bone Density; Calcitriol; Calcium; Dietary Supplements; Etidronic Acid; Femu | 2001 |
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid; Fem | 1992 |
Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
Topics: Etidronic Acid; Humans; Hypercalcemia; Infusions, Intravenous; Neoplasms; Pilot Projects; Time Facto | 1991 |
Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
Topics: Double-Blind Method; Etidronic Acid; Female; Fluid Therapy; Humans; Hypercalcemia; Infusions, Intrav | 1991 |
A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Creatinine; Double-Blind Method; Etidronic Acid; Female; | 1991 |
Clinical trials of gallium nitrate in patients with cancer-related hypercalcemia.
Topics: Antineoplastic Agents; Calcitonin; Clinical Trials as Topic; Double-Blind Method; Drug Administratio | 1991 |
Study in 25 patients shows gallium nitrate superior therapy for hypercalcemia in cancer patients.
Topics: Antineoplastic Agents; Calcium; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms | 1990 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Topics: Adult; Aged; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Furosem | 1986 |
Etidronate disodium in the management of malignancy-related hypercalcemia.
Topics: Adult; Aged; Calcium; Double-Blind Method; Etidronic Acid; Female; Humans; Hypercalcemia; Male; Midd | 1987 |
Maintenance etidronate in the prevention of malignancy-associated hypercalcemia.
Topics: Administration, Oral; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Humans; | 1987 |
Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
Topics: Administration, Oral; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Humans | 1987 |
49 other studies available for etidronate and Hypercalcemia
| Article | Year |
|---|---|
Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy.
Topics: Bone Density Conservation Agents; Etidronic Acid; Fat Necrosis; Humans; Hypercalcemia; Hypoxia-Ische | 2014 |
Hypercalcemia in patients with disseminated coccidioidomycosis.
Topics: Adult; Aged; Calcium; Coccidioidomycosis; Diphosphonates; Etidronic Acid; Female; Humans; Hypercalce | 2004 |
Uncommon localization of calcinosis cutis after liver transplantation.
Topics: Adult; Bone Density Conservation Agents; Calcinosis; Etidronic Acid; Graft Rejection; Humans; Hyperc | 2005 |
Subcutaneous fat necrosis with hypercalcemia.
Topics: Administration, Oral; Bone Density Conservation Agents; Calcium; Diuretics; Etidronic Acid; Fat Necr | 2006 |
[Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis].
Topics: Adipose Tissue; Calcinosis; Etidronic Acid; Female; Humans; Hypercalcemia; Infant; Kidney Diseases; | 2007 |
The use of diphosphonates in myeloma.
Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma | 1983 |
[Diphosphonates in the treatment of hypercalcemia].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyr | 1984 |
Disodium etidronate in hypercalcaemia due to immobilisation.
Topics: Adolescent; Adult; Cervical Vertebrae; Etidronic Acid; Fracture Fixation; Fractures, Closed; Humans; | 1984 |
Immobilization hypercalcemia in acute spinal cord injury treated with etidronate.
Topics: Acute Disease; Adult; Etidronic Acid; Humans; Hypercalcemia; Immobilization; Male; Spinal Cord Injur | 1984 |
Effects of disodium etidronate in murine tumor models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Etidronic Acid; Hypercalcemia | 1984 |
[Hypercalcemic syndromes].
Topics: Adrenal Cortex Hormones; Adult; Benzothiadiazines; Child; Diphosphonates; Diuretics; Etidronic Acid; | 1984 |
New diphosphonates to block bone resorption.
Topics: Animals; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Eti | 1980 |
Parenteral diphosphonates for treating malignant hypercalcemia.
Topics: Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration | 1981 |
Treatment of hypercalcemia with etidronate disodium.
Topics: Etidronic Acid; Female; Humans; Hypercalcemia | 1980 |
Tumoral calcinosis. Observations during six years.
Topics: Amyloidosis; Biopsy; Calcinosis; Etidronic Acid; Female; Humans; Hypercalcemia; Lipoproteins, VLDL; | 1980 |
[Treatment of hypercalcemia of tumoral origin with two diphosphonates].
Topics: Adult; Aged; Bone Resorption; Bronchial Neoplasms; Diphosphonates; Esophageal Neoplasms; Etidronic A | 1980 |
[Treatment of neoplastic hypercalcemia with ethane 1-hydroxy-1 diphosphonate in low dosage].
Topics: Aged; Bronchial Neoplasms; Etidronic Acid; Humans; Hypercalcemia; Male | 1982 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
Case report: hypercalcemia in acute myeloblastic leukemia is caused by osteoclast activation.
Topics: Biopsy; Bone and Bones; Bone Marrow; Cytarabine; Etidronic Acid; Humans; Hypercalcemia; Leukemia, My | 1993 |
Successful treatment of immobilization hypercalcemia using calcitonin and etidronate.
Topics: Adolescent; Adult; Bone Resorption; Calcitonin; Drug Therapy, Combination; Etidronic Acid; Female; H | 1993 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m.
Topics: Administration, Oral; Aged; Bone and Bones; Bone Diseases; Bone Neoplasms; Contraindications; Drug I | 1997 |
Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro.
Topics: Animals; Arteries; Calcium Channel Blockers; Clodronic Acid; Diphosphonates; Drug Synergism; Etidron | 1998 |
The use of etidronate in therapy-resistant hypercalcemia.
Topics: Adolescent; Etidronic Acid; Head and Neck Neoplasms; Humans; Hypercalcemia; Male; Rhabdomyosarcoma, | 1999 |
Etidronate in subcutaneous fat necrosis of the newborn.
Topics: Etidronic Acid; Fat Necrosis; Humans; Hypercalcemia; Infant, Newborn | 1999 |
Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barré syndrome.
Topics: Administration, Oral; Child; Etidronic Acid; Guillain-Barre Syndrome; Humans; Hypercalcemia; Hypokin | 2001 |
Effects of diphosphonate and colchicine administration upon acid-base changes induced in rats by bilateral nephrectomy.
Topics: Acid-Base Equilibrium; Acids; Animals; Colchicine; Etidronic Acid; Hydrogen-Ion Concentration; Hydro | 1979 |
[Calcium kinetics of myocardium in experimental hypercalcemia and isoproterenol lesions--ultrastructural and roentgen microanalytical findings].
Topics: Animals; Calcinosis; Calcium; Dihydrotachysterol; Etidronic Acid; Heart; Hypercalcemia; Isoprotereno | 1978 |
[The diagnosis of pulmonary calcinosis by scintigraphy (author's transl)].
Topics: Adolescent; Adult; Aged; Calcinosis; Diagnosis, Differential; Etidronic Acid; Female; Glomerulonephr | 1976 |
Primary hyperparathyroidism in an elderly patient with multiple myeloma.
Topics: Aged; Aged, 80 and over; Calcium; Cyclic AMP; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyroi | 1992 |
Management of acute hypercalcemia.
Topics: Acute Disease; Etidronic Acid; Humans; Hypercalcemia | 1992 |
Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy.
Topics: Aged; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Drug Interactions; | 1992 |
Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.
Topics: Animals; Calcitonin; Calcium; Drug Therapy, Combination; Etidronic Acid; Humans; Hypercalcemia; Inje | 1992 |
Etidronate sodium therapy--a cause of poor skeletal radiopharmaceutical uptake.
Topics: Aged; Bone and Bones; Etidronic Acid; Humans; Hypercalcemia; Male; Middle Aged; Radionuclide Imaging | 1991 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp | 1991 |
Malignant hypercalcemia. The choice of therapy.
Topics: Etidronic Acid; Fluid Therapy; Humans; Hypercalcemia; Neoplasms | 1991 |
Duration of etidronate effect demonstrated by serial bone scintigraphy.
Topics: Aged; Bone and Bones; Drug Interactions; Etidronic Acid; Humans; Hypercalcemia; Male; Radionuclide I | 1991 |
Cyclical etidronate treatment of osteoporosis.
Topics: Binding, Competitive; Bone and Bones; Diphosphonates; Etidronic Acid; Female; Humans; Hypercalcemia; | 1990 |
Hypercalcaemia in malignancy.
Topics: Diphosphonates; Etidronic Acid; Fluid Therapy; Humans; Hypercalcemia; Neoplasms | 1989 |
Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
Topics: Adult; Aged; Aged, 80 and over; Calcifediol; Calcitriol; Calcium; Creatinine; Cyclic AMP; Etidronic | 1987 |
Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate.
Topics: Adult; Aged; Bone and Bones; Calcitonin; Calcium; Drug Therapy, Combination; Etidronic Acid; Humans; | 1986 |
Rationale for diphosphonate therapy in hypercalcemia of malignancy. Introduction.
Topics: Bone Neoplasms; Etidronic Acid; Humans; Hypercalcemia; Kidney; Osteoclasts; Paraneoplastic Endocrine | 1987 |
Etidronate disodium: a new therapy for hypercalcemia of malignancy. Proceedings of a symposium.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Paraneoplastic Endocrine Syndromes | 1987 |
Effect of etidronate disodium on the interactions between malignancy and bone.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Etidronic Acid; Hypercalcemia; Mice; Osteolysis; Par | 1987 |
Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Topics: Aged; Bone and Bones; Bone Diseases, Metabolic; Calcium; Etidronic Acid; Female; Humans; Hydroxyprol | 1987 |
Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry.
Topics: Bone and Bones; Calcium; Etidronic Acid; Humans; Hypercalcemia; Osteitis Deformans; Paraneoplastic E | 1987 |
[Failure of cimetidine and etidronate disodium to suppress parathyroid hormone level and hypercalcemia in primary hyperparathyroidism].
Topics: Adenoma; Aged; Alkaline Phosphatase; Cimetidine; Etidronic Acid; Humans; Hypercalcemia; Hyperparathy | 1988 |
Intravenous etidronate in the management of malignant hypercalcemia.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Etidronic Acid; Female; Head and N | 1985 |
[Hypercalcemia with elevation of parathormone in lymphocytic lymphoma. Efficacy of ethanehydroxydiphosphonate by mouth].
Topics: Bone Resorption; Etidronic Acid; Female; Humans; Hypercalcemia; Lymphocytes; Lymphoma; Middle Aged; | 1985 |